Definium Therapeutics Q3 loss narrows on warrant gain, higher interest income

Overview

• US biopharma firm's Q3 net loss narrowed from prior year as warrant gains offset higher costs

• Company reported positive Phase 3 DT120 ODT results in GAD and received FDA Breakthrough Therapy designation in MDD

• Cash and investments rose to $1.05 bln, expected to fund operations into 2030

Outlook

• Definium expects to file DT120 ODT NDA in H1 2027

• Company expects topline data from Phase 3 Ascend study in MDD in 2027

• Definium plans to start Phase 3 Haven study in PTSD in 2027

Result Drivers

• HIGHER R&D SPEND - Q3 R&D expenses rose due to increased personnel costs and higher spending on the DT120 development program

• G&A EXPENSES UP - General and administrative costs increased, driven by commercial-preparedness, corporate affairs, and personnel expansion

• WARRANT GAIN & INTEREST INCOME - Net loss narrowed on a $12.4 mln warrant revaluation gain and higher interest income, partly offset by increased operating expenses

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Definium Therapeutics Inc is $70.00, about 110.4% above its November 6 closing price of $33.27

Reuters Recommended Reads

• Nov 9 - Bicara Therapeutics Q3 net loss widens on higher R&D costs

• Nov 9 - Spruce Biosciences Q3 net loss widens on higher R&D costs

• Nov 9 - Neurogene Q3 net loss widens on higher R&D and G&A costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)